Fenben lab fenbendazol is an antiparasitic agent that is used in animals and humans to treat gastrointestinal parasites. It exerts polymerization inhibitory effects on tubulin, a component of microtubules. These structures provide structure and shape to cells and are involved in cell division. Anticancer agents that act on microtubules include the vinca alkaloids (vinblastine, vinorelbine, and vindesine) and taxanes (paclitaxel and docetaxel).
Febantel is a pro-benzimidazole that was developed by Bayer in 1975. It is converted in the liver to fenbendazole and the fenbendazole sulfoxide (oxfendazole). Febantel is used for treatment of intestinal helminths in dogs, cats, sheep, goats, cattle, and rabbits. It is also effective against Giardia in dogs and pulmonary helminths, including lungworms and flukes, in cats. It is generally well tolerated, although vomiting and diarrhea may occur in some pets.
In vitro studies on EMT6 cellular proliferation have shown that high doses of fenbendazole reduce clonogenicity and cell numbers, suggesting that this compound could have cytostatic, rather than cytotoxic, properties. In the present study, we tested a range of doses of fenbendazole in mice with established EMT6 tumors. These animals were anesthetized with 100 mg/kg ketamine and 10 mg/kg xylazine prior to treatment and were irradiated locally with 250 kV gamma radiation using a Siemens Stabilipan at the Duke University Radiation Medicine Center.
Tumor growth was monitored by measuring the time taken for each animal to grow from a given volume to four times that volume. In all groups of mice, fenbendazole reduced tumor growth. However, the difference between the irradiated groups and the unirradiated control group was not significant. fenben lab fenbendazol